Impact of estradiol structural modifications (18-methyl and/or 17-hydroxy inversion of configuration) on the in vitro and in vivo estrogenic activity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 127, Issue 3-5, 2011, Pages 324-330

  Ayan, Diana ^a   Roy, Jenny ^a   Maltais, René ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 Hydroxysteroid dehydrogenase; Conformation; Estradiol; Estrogen receptor; Stereochemistry; Steroid

Indexed keywords

17ALPHA ESTRADIOL; 18 EPI 17ALPHA ESTRADIOL; 18 EPI 17BETA ESTRADIOL; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; EPIMER; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOMER; NONHUMAN; RAT; RECEPTOR AFFINITY; SYNTHESIS; UTERUS; VAGINA;

ANIMALS; CELL LINE; ESTRADIOL; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; RECEPTORS, ESTROGEN;

MUS;

EID: 81255157810     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2011.07.009     Document Type: Article

References (41)

1. National Cancer Institute (USA). http://www.cancer.gov/cancertopics/ types/breast.
2. J.R. Pasqualini, and G.S. Chetrite Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer J. Steroid Biochem. Mol. Biol. 93 2005 221 236 (Pubitemid 40602495)
3. J.S. Lewis, and V.C. Jordan Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance Mutat. Res. 591 2005 247 263 (Pubitemid 41654853)
4. D. Poirier New cancer drugs targeting the biosynthesis of estrogens and androgens Drug Dev. Res. 69 2008 304 318
5. S. Marchais-Oberwinkler, C. Henn, G. Moller, T. Klein, M. Negri, A. Oster, A. Spadaro, R. Werth, M. Wetzel, K. Xu, M. Frotscher, R.W. Hartmann, and J. Adamski 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic target: protein, structures, functions, and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 125 2011 66 82
6. D. Poirier 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review Expert Opin. Ther. Patents 20 2010 1123 1145
7. M. Meier, G. Moller, and J. Adamski Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease Ann. N.Y. Acad. Sci. 1155 2009 15 24
8. D. Poirier Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases Anti-Cancer Agents Med. Chem. 9 2009 642 660
9. P. Brozic, T. Lanisnik Risner, and S. Gobec Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 15 2008 137 150
10. J.M. Day, H.J. Tutill, A. Purohit, and M.J. Reed Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer 15 2008 665 692
11. S. Nagasaki, Y. Miki, J. Akahira, T. Suzuki, and H. Sasano 17beta-Hydroxysteroid dehydrogenases in human breast cancer Ann. N.Y. Acad. Sci. 1155 2009 25 32
12. T.M. Penning 17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design Endocr. Relat. Cancer 3 1996 41 56 (Pubitemid 26151990)
13. Y. Laplante, C. Rancourt, and D. Poirier Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors Mol. Cell. Endocrinol. 301 2009 146 153
14. D. Poirier Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases J. Steroid Biochem. Mol. Biol. 125 2011 83 94
15. + breast cancer cell proliferation induced by estrone Bioorg. Med. Chem. 16 2008 1849 1860 (Pubitemid 351226579)
16. C. Cadot, Y. Laplante, F. Kamal, V. Luu-The, and D. Poirier C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: chemical synthesis and biological evaluation Bioorg. Med. Chem. 15 2007 714 726 (Pubitemid 44880729)
17. R.A. Hughes, T. Harris, E. Altmann, D. McAllister, R. Vlahos, A. Robertson, M. Cushman, Z. Wang, and A.G. Stewart 2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding Mol. Pharmacol. 61 2002 1053 1069 (Pubitemid 34441770)
18. G.M. Allan, H.R. Lawrence, J. Cornet, C. Bubert, D.S. Fischer, N. Vicker, A. Smith, H.J. Tutill, A. Purohit, J.M. Day, M.F. Mahon, M.J. Reed, and B.V. Potter Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 49 2006 1325 1345 (Pubitemid 43273497)
19. A. Sievernich, L. Wildt, and H. Lichtenberg-Frate In vitro bioactivity of 17alpha-estradiol J. Steroid Biochem. Mol. Biol. 92 2004 455 463
20. M. Perusquia, and E. Navarrete Evidence that 17alpha-estradiol is biologically active in the uterine tissue: antiuterotonic and antiuterotrophic action Reprod. Biol. Endocrinol. 3 2005 30
21. C. Gwilliam, A. Paquet, D.G. Williamson, and D.S. Layne Isolation from rabbit urine of the 3-glucuronide-17-N-acetylglucosaminide of 17 alpha-estradiol Can. J. Biochem. 52 1974 452 455
22. G. Hobe, R. Schon, N. Goncharov, G. Katsiya, M. Koryakin, I. Gesson-Cholat, M. Oettel, and H. Zimmermann Some new aspects of 17alpha-estradiol metabolism in man Steroids 67 2002 883 893 (Pubitemid 35286746)
23. M. Gutierrez, A.I. Fernandez, M.P. Revuelta, B. Cantabrana, and A. Hidalgo Partial contribution of polyamines to the relaxant effect of 17 alpha-estradiol in rat uterine smooth muscle Gen. Pharmacol. 30 1998 71 77 (Pubitemid 27497222)
24. J. Neuwinger, I. Muck, J. Esper, and L. Wildt Selektive behandlung von hitzewallungen mit 17α-östradiol, einem östradiol-epimer ohne klassische östrogenwirkung Menopause 8 1996 9 30
25. J.A. Dykens, W.H. Moos, and N. Howell Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical study Ann. N.Y. Acad. Sci. 1052 2005 116 135 (Pubitemid 41338962)
26. P.S. Green, J. Bishop, and J.W. Simpkins 17alpha-Estradiol exerts neuroprotective effects on SK-N-SH cells J. Neurosci. 17 1997 511 515 (Pubitemid 27024564)
27. E. Perez, C. Zu Yun, D.F. Covey, and J.W. Simpkins Neuroprotective effects of estratriene analogs: structure-activity relationship and molecular optimization Drug Dev. Res. 66 2006 78 92 (Pubitemid 43363962)
28. W.H. Moos, J.A. Dykens, D. Nohynek, E. Rubinchik, and N. Howell Review of the effects of 17α-estradiol in humans: a less feminizing estrogen with neuroprotective potential Drug Dev. Res. 70 2009 1 21
29. K. Don Yi, E. Perez, S. Yang, R. Liu, D.F. Covey, and J.W. Simpkins The assessment of non-feminizing estrogens for use in neuroprotection Brain Res. 1379 2011 61 70
30. G.M. Anstead, K.E. Carlson, and J.A. Katzenellenbogen The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site Steroids 62 1997 268 303 (Pubitemid 27114399)
31. B. Schonecker, C. Lange, M. Kotteritzsch, W. Gunther, J. Weston, E. Anders, and H. Gorls Conformational design for 13alpha-steroids J. Org. Chem. 65 2000 5487 5497
32. T.D.W. Claridge High-Resolution NMR Techniques in Organic Chemistry 1999 Elsevier Science Ltd. Oxford, UK
33. J. Asselin, and F. Labrie Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat J. Steroid Biochem. 9 1978 1079 1082 (Pubitemid 9052727)
34. J. Asselin, P.A. Kelly, M.G. Caron, and F. Labrie Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin Endocrinology 101 1977 666 671 (Pubitemid 8191151)
35. C. Kramer Extension of multiple range tests to group with unique numbers of replications Biometrics 12 1956 307 310
36. T.H. Charn, E.T. Liu, E.C. Chang, Y.K. Lee, J.A. Katzenellenbogen, and B.S. Katzenellenbogen Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection Mol. Endocrinol. 24 2010 47 59
37. xxx www.atcc.org.
38. Z. Weihua, S. Saji, S. Makinen, G. Cheng, E.V. Jensen, M. Warner, and J.A. Gustafsson Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus Proc. Natl. Acad. Sci. U.S.A. 97 2000 5936 5941 (Pubitemid 30367502)
39. R.M. Blair, H. Fang, W.S. Branham, B.S. Hass, S.L. Dial, C.L. Moland, W. Tong, L. Shi, R. Perkins, and D.M. Sheehan The estrogen receptor relative structure binding affinities of 188 natural and xenochemicals: structural diversity of ligands Toxicol. Sci. 54 2000 138 153 (Pubitemid 30152465)
40. S.C. Brooks, and D.F. Skafar From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells Steroids 69 2004 401 418 (Pubitemid 38829336)
41. W. Duax, D. Ghosh, V. Pletnev, and J.F. Griffin Three-dimensional structures of steroids and their protein targets Pure Appl. Chem. 68 1996 1297 1302 (Pubitemid 126495460)